IL1B and COVID-19: MABs have been directed against various molecules like granulocyte monocyte colony stimulating factor (GM‐CSF), IFN‐γ, IL‐1β, chemokines etc. to fight against COVID‐19, such as Mavrilimumab (formerly CAM‐3001).